America's opioid crisis triggers first corporate fine

An Oklahoma judge has ordered Johnson & Johnson to pay $572m – much less than expected – in the first trial involving a state seeking compensation for the public-health crisis spawned by opioid painkillers.

Container of Johnson's baby powder © Justin Sullivan/Getty Images

Container of Johnson's baby powder © Justin Sullivan/Getty Images

Shares in Johnson & Johnson (J&J) jumped by more than 5% this week. No wonder, says Jan Hoffman on Bloomberg. An Oklahoma judge ordered the company to pay "far less" than expected in the first trial involving a state seeking compensation for the public-health crisis spawned by opioid painkillers.

The judge said J&J had created a "temporary" public nuisance by "duping" doctors into overprescribing its opioid-based medications. But the $572m payment was much lower than the $17.5bn Oklahoma had been seeking. The case has been closely monitored by around two-dozen opioid makers, distributors and retailers facing more than 2,000 similar lawsuits around the US.

The verdict may have given investors "some hope" that opioid litigation "won't be as destructive as some on Wall Street have feared", says Charley Grant in The Wall Street Journal. However, they should "hold the celebration" since the "cloud hanging over drug stocks won't clear up soon". Future lawsuits will be heard in different courts. The unpredictable nature of litigation means these companies "could owe nothing; a sum that bankrupts them and sends their share prices to zero; or any outcome in between".

The judgment was "important for reasons that go beyond the dollar figure attached to it", says Jay Willis for gq.com. It was based on "public nuisance...theory", the same principle behind the "massive lawsuits filed against the tobacco industry in the mid-1990s". That led to a $250bn payment "the largest civil settlement in US history".

Recommended

Investor optimism ebbs in Indian stockmarkets
Emerging markets

Investor optimism ebbs in Indian stockmarkets

India’s BSE Sensex stockmarket index has fallen by almost 8% so far this year. Interest rates are on the rise, and foreign investors have been selling…
18 May 2022
Value is starting to emerge in the markets
Investment strategy

Value is starting to emerge in the markets

If you are looking for long-term value in the markets, some is beginning to emerge, says Merryn Somerset Webb. Indeed, you may soon be able to buy tra…
16 May 2022
Interest-rate rises mean more pain for stocks
Stockmarkets

Interest-rate rises mean more pain for stocks

Interest rates are rising around the world as central banks try to get inflation under control. That’s hitting stockmarkets – and there is more pain t…
13 May 2022
Anna Macdonald and Mikhail Zverev: Investing in innovative new frontiers
Investment strategy

Anna Macdonald and Mikhail Zverev: Investing in innovative new frontiers

Merryn talks to Anna Macdonald and Mikhail Zverev of Amati about investing in growth-focused innovation in the teeth of a tech-stock selloff, and the …
12 May 2022

Most Popular

Get set for another debt binge as real interest rates fall
UK Economy

Get set for another debt binge as real interest rates fall

Despite the fuss about rising interest rates, they’re falling in real terms. That will blow up a wild bubble, says Matthew Lynn.
15 May 2022
Is the oil market heading for a supply glut?
Oil

Is the oil market heading for a supply glut?

Many people assume that the high oil price is here to stay – and could well go higher. But we’ve been here before, says Max King. History suggests tha…
16 May 2022
Value is starting to emerge in the markets
Investment strategy

Value is starting to emerge in the markets

If you are looking for long-term value in the markets, some is beginning to emerge, says Merryn Somerset Webb. Indeed, you may soon be able to buy tra…
16 May 2022